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1.1 Heart development 
 
The heart is one of the first embryonic organs to start functioning. It originates 
from the splanchnic mesoderm. One of the first event that occurs during heart 
development is the specification and migration of cardiac precursor cells. At the 
earliest stages of heart formation, two pools of cardiac precursors are present: the 
First Heart Field (FHF), which contributes to the left ventricle, and the second 
heart field (SHF), which gives rise to a large portion of the heart, including the 
right ventricle first and to the outflow tract, sinus venosus and left and right atria  
later. SHF is subdivided into several lineage pools which contribute either to 
anterior structures or posterior components. These findings explain why mutations 
associated with congenital cardiac diseases result in defects of specific heart 
structures. The following step in heart formation is the movement of cardiac 
precursors which aggregate forming the “heart tube” [1]. In human development, 
during this phase the heart starts beating. After the formation of the heart tube, 
two epithelial layers, separated by an acellular matrix, called “cardiac jelly”, are 
observed. These two layers are the myocardium and the endocardium [2]. Hence 
the heart tube is made up of three layers: the outer one, called epicardium, the 
middle one, myocardium, and the inner layer, endocardium. 
During the course of development, the heart loops towards the right side and 
subsequently the atrial and ventricular segments become recognizable. The 
following phase is characterized by the formation of septa which give rise to two 
atria, two ventricles, two atrioventricular canals (which will become valves) and 
the outflow tract (Figure 1A). Later, endocardial cells move into the cardiac jelly 
forming the “cardiac cushion” which will give rise to the atrioventricular valves, 
and the ventricular septation arises from myocardium from the left and right 
ventricles. Following the formation of the “primary atrium septum” and the 
“secondary atrium septum” the separation of atria into right and left portions 
occurs. The latest event concerning septation of the heart occurs in the outflow 
tract region where the common outflow is divided into the aorta, connected to the 
left ventricle, and pulmonary artery, connected to the right ventricle (Figure. 1B) 
[3]. At the end of the septation process, part of the outflow tract disappears and 
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part becomes incorporated into the ventricular chambers. Thus, the flanking 
segments are no longer identifiable in the fetal heart. 
The mechanisms involved in heart development are finely regulated  by a 
complex network of genes which are differentially expressed in the cardiac 
compartments. These genes code for cardiac-specific transcription factors, 
contractile proteins, proteins involved in calcium handling and impulse 
conduction, for cell-cell and cell-matrix contact molecules. In the last years, a new 
class of molecules, called microRNAs, have been demonstrated to play a 
fundamental role during cardiac development. 
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Figure 1. Heart development. Early steps in heart development (A). Maturation of the 
heart (B) [3]. 
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1.2 MicroRNA 
1.2.1 MicroRNA: from yesterday to nowadays 
 
MicroRNAs (miRNAs) are short endogenous single-strand RNA molecules (21-
23 nucleotides in length) that inhibit mRNA target translation.  
MiRNAs were described, for the first time, in 1993 in Caenorhabditis elegans by 
Lee and colleagues. The authors found a small non-coding RNA, called Lin-4, 
which was able to inhibit the translation of Lin-14 mRNA during the larval 
development  [4]. However, this evaluation came from many studies performed in 
Caenorhabditis elegans starting from 1981, when Chalfie and colleagues found a 
loss of function mutation in the gene of lin-4 which led to a constitutive 
expression of larval-specific genes [5]. Eight years later, another group of 
researchers demonstrated that lin-4 was able to inhibit the expression of two 
genes, lin-14 and lin-28, involved into the larva-to-adult developmental switch 
[6]. Later, in 1991, through deletion experiments, it was found that the interaction 
between lin-4 and lin-14 was required to down-regulate lin-14 protein levels 
during development [7]. Finally, thanks to these discoveries, in 1993, Lee and 
colleagues described lin-4 as a small-non coding RNA which was a negative 
regulator of lin-14 mRNA; the authors also found that Lin-4 RNA sequences were 
complementary to the 3’untranslated region of the Lin-14 messenger, suggesting a 
potential specific-sequence interaction [4]. Some years later, the discovery of 
another non-coding small RNA, allowed the development of the  research field on 
miRNAs. In a study performed in 2000 by  Reinhart and colleagues, a small RNA 
(21-nucleotides in length), let-7, was described as a regulatory RNA highly 
conserved among the species [8]. This finding opened the way to other studies 
that finally recognized the class of small non-coding RNA as a novel class of 
regulators for gene expression, called microRNAs [9]. 
At present, for the microRNA study, scientists use a database, called, miRBase 
(http://www.mirbase.org/) that is actually the primary online repository for all 
microRNA sequences and annotation. To date, the current release (miRBase 17) 
contains over 16000 microRNA gene loci in over 150 species, and over 19000 
distinct mature microRNA sequences. That means that the miRNA field is rapidly 
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growing, considering that over 2000 miRNA sequences have been already 
described in vertebrates, flies, worms and plants, and even in viruses. 
 
1.2.2 Biogenesis 
 
MiR genes are localized either in independent units, with their own promoter, or 
in introns (“intronic miRNAs”) of protein coding genes [10].  
MiR are first transcribed as long primary miRNA transcripts (“pri-miRs”) by 
RNA polymerase II inside the nucleus; pri-miR contains a stem-loop structure, a 
cap at 5’-end and a poly-A tail at 3’-end [11]. Then, pri-miR is cleaved by the 
enzymatic complex called “microprocessor” in molecules of 70-100 nt in length 
that take name of “pre-miR” [12]. The microprocessor complex is composed by 
the ribonuclease III Drosha and its cofactor Di George syndrome critical region 
gene 8 (DGCR8), a double-strand RNA binding protein required for binding the 
RNA ds substrate and for facilitating cleavage by Drosha positioning its catalytic 
sites in the proper manner [13]. 
Cleavage releases a pre-miR hairpin that is typically ≈ 55–70 nt in length. The 2 
nt 3’overhangs of pre-miR hairpin are recognized by Exportin-5 (Exp-5), which is 
a member of the nuclear transport receptor family, and its partner Ran-GTP, that 
allows the passage into cytoplasm (Exp-5 binds cooperatively its cargo and its 
cofactor Ran-GTP: the hydrolysis of GTP allows the cargo release in the 
cytoplasm) [14]. Here, a second cleavage is generated by the enzyme Dicer, 
another member of the ribonuclease III family highly conserved among species, 
which gives rise to 22 nt small RNA duplexes. Dicer associates with ds-RNA-
binding proteins, like transactivation-response element RNA-binding protein 
(TRBP) and p53-associated cellular protein (PACT), which contain dsRNA-
binding domains for pre-miR processing [15], [16]. RNA duplex is unwound by 
helicase activity of Dicer and one of the strands is preferentially incorporated into 
Argonaute (Ago) protein so as to generate the effector complex RNA induced 
silencing complex (RISC) [17]. Ago proteins are identified by three characteristic 
domains: N-terminal PAZ domain, the middle MID domain and the C-terminal 
PIWI domain [18]. Ago family is very large and it includes several members like 
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Ago1, Ago2, Ago3. Ago2 seems to be able, alone, to form a cleavage-competent 
RISC [19].  
Strand selection of miRNA may be determined by the relative thermodynamic 
stability of the two ends of miRNA duplexes [20]:  the strand with less stability at 
the 5’-end (typically a GU pair instead of GC pair) is loaded onto RISC, whereas 
the other strand, the passenger (miR*), is released [21].  
At first it was thought that miR* was degraded soon after its release. However, 
many evidences demonstrate that miRs* are often present at physiologically levels 
[22], and that they have many biological roles, for example miR-378* has been 
identified as a molecular switch in breast cancer cells [23], and miR-155* 
(together with miR-155) is involved in regulating human plasmacytoid dendritic 
cell (PDC) activation [24]. Furthermore, substantial fraction of miR* species are 
stringently conserved over vertebrate evolution, they exhibit greatest conservation 
in their seed regions, and define complementary motifs whose conservation across 
vertebrate 3′-UTR evolution is statistically significant [25].  
Moreover, it was found that a significant fraction of pre-miR hairpins produces  
miR* species whose seed sequence recognizes 3’UTR target site. That means that 
miR* are not present just in cells, but they also acquired endogenous regulatory 
target [22].  
However, according to the official nomenclature, miR* indicates the miR strand 
which is  weakly expressed. If it is not known which of the two strands is more 
expressed than the other, usually it can be found the indication “miR-5p” and 
“miR-3p” depending on the position on the genome (5’ or 3’-arm of the hairpin).  
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Figure 2. MicroRNA 
biogenesis and their 
assembly into 
ribonucleoproteins 
[26]  
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1.2.3 How do microRNAs work?  
 
MicroRNAs have been proposed as “micromanagers” of gene expression, because 
they might act as on-off switches to eliminate mRNAs that should not be 
expressed in a specific cell type or at a specific moment. They also can regulate 
mRNAs abundance, adjusting levels within physiological range [27]. 
MicroRNAs interact with their mRNA targets by base pairing. In plants, most 
microRNAs base pair to mRNAs with perfect complementarity, inducing mRNA 
degradation by a cleavage in the middle of the miRNA-mRNA duplex [28].  
In the case of metazoans, generally, the interaction between miRNA and its target 
is imperfect [29]. The region responsible of this interaction is called “seed 
sequence” and it corresponds to the nucleotide 2 to 8 (nucleotide 1 is the first one 
from 5’-end) (Figure 3). Just for thermodynamic reasons, an A nucleotide across 
position 1, and an A or U across position 9, improve the site efficiency, even if 
they don’t need to base pair with miRNA nucleotides [30]. Furthermore, there 
must be a complementarity to the miRNA 3’ half to stabilize the interaction, even 
if mismatches and bulges (structural motifs formed following a mismatch in the 
miRNA : mRNA hetroduplex) are tolerated in this region, but, if the interaction 
with seed region is not perfect, there should be a good base pair to residues 13-16 
of the miRNA to give a good stability [31], [29]. 
 
 
 
 
Figure 3. microRNA-mRNA interaction [26] 
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Furthermore, there are many factors that influence the site efficiency, among 
which an AU-rich neighborhood and, in case of long 3’-UTRs, a position not so 
far away from the poly-A tail or the termination codon, so that to make binding 
sites more accessible [29], [32].  In contrast with these rules, there are many cases 
in which a bulged nucleotide in the seed region is required for an efficient 
repression miRNA-mediated [26]. 
Typically, more than one miRNA binding site is  present on 3’UTR of mRNA 
target and multiple sites for the same or different miRNAs are required for 
effective repression [32], [31], [30], [29]. When they are localized close to each 
other they act cooperatively providing a stronger repression [30], [29]. 
MiRNAs act either inhibiting mRNA translation or inducing degradation of target. 
When the association miRNA-mRNA target presents several mismatches and 
bulges, it results in a reduced efficiency of translation rather than in a decrease in 
mRNA abundance [33]. The inhibition of mRNAs translation can occur at the 
initiation or post-initiation step. In repression at the initiation step, Ago2 protein is 
the main actor: it has a MC domain (cap-binding like domain) which bind the 
m
7G cap of mRNA precluding the recruitment of eIF4E and, therefore, the 
assembly of translation complex [34].  
For the repression at post-initiation step a drop-off model is proposed: miRNAs 
render ribosome prone to premature termination of translation [35]. When 
miRNAs bind with a strong complementarity to their target, the mRNA 
degradation is induced by deadenylation in 3’  5’ direction catalyzed by the 
exosome, or by the removal of the cap followed by 5’  3’ degradation catalyzed 
by the exoribonuclease-1 (XRN1) [26]. 
Degradation or, at least, its final steps, seems to occur in P-bodies, that are 
granules localized in the cytoplasm enriched in mRNA-catabolyzing enzymes and 
translational repressors [36], [37] (Figure 4). P-bodies are also enriched in Ago 
proteins and miRNAs. Originally they were considered as being primarily 
involved in mRNA degradation, but now it is clear that P-bodies are also 
temporary sites of storage of repressed mRNAs [26].  
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In particular situations, like following a stress, the mRNA sequestration in P-
bodies can be irreversible and it can be released and translated after the interaction 
with polysomes [38].  
Studies that look at a better understanding of miRNAs function always go on and 
many models are continuously proposed. 
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Figure 4. Possible mechanisms of the microRNAs mediated post-transcriptional 
gene repression in animal cells [26] 
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1.2.4 MiRNA prediction target 
 
To appreciate the significance of a change in miRNA levels during a particular 
cellular process, the identification of their own mRNA targets is crucial. To 
achieve this purpose many computational prediction target tools, based on specific 
algorithms, have been developed. The most widely utilized engines are miRanda 
(www.microrna.org), TargetScan (www.targetscan.org) and PicTar 
(www.pictar.mdc-berlin.de). They are based on algorithms which rely on base- 
paring between “seed sequence” of the miRNA and the 3’-UTR sequence of the 
mRNA target but miRNA target sites are localized also within the coding region 
of a gene even if at much lower frequency. Each engine uses different algorithms 
to establish the alignment score.  
MiRanda calculates the alignment score as the sum of match and mismatch 
scores, including G:U wobbles and gap penalties. Since sequence conservation is 
a strong indication of functional constraints in evolution, miRanda prediction 
software also considers the degree of evolutionary conservation of the targeted 
sequence and its position in 3’-UTRs of human, mouse and rat genes [39].  
TargetScan prediction software applies an alignment score for Watson-Crick base-
pairing in the seed sequence (nucleotides 2-7) of the miRNA to its target and also 
base-pairing beyond the seed sequence that can compensate for mismatches in the 
seed. It also recognizes a conserved adenosine at the first position and/or a W-C 
match at position 8, and considers the degree of conservation using three different 
levels: highly conserved between human, rat, mouse, dog, and chicken; conserved 
between human, mouse, rat, and dog; poorly conserved among any combination 
of species [29], [40].  
The third target prediction software is PicTar that takes into account a perfect W-
C base paired 7 nucleotides seed (1-7 or 2-8) allowing mismatches if the free 
binding energy does not increase, the binding energy of the entire miRNA-mRNA 
duplex, and the degree of conservation of targeted sites between all the species 
(chimpanzee, pufferfish and zebrafish) [41]. 
Another important criterion that should be considered during miRNA target 
prediction is the accessibility of the target site. In fact when the target site is 
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localized in a closed stem structure, the inhibition by miRNA is not allowed. For 
this reason a prediction software, called Probability of Interaction by Target 
Accessibility (PITA) was designed; which allows prediction of target sites by first 
searching for complementary seed sequences, and then calculating the free 
binding-energy after substracting the energy used to unwind any predicted 
secondary structure [42]. 
 
1.2.5 miRNAs in the heart: implications in cardiac development and diseases  
 
MiRNAs are involved in several physiological and pathological processes as 
development, apoptosis, cell differentiation, metabolism and cancer and they are 
often tissue-specific; for example miR-122 is liver-specific, miR-142 and miR-
223 are expressed in the hematopoietic system, miR-9, miR-124 and miR-128 are 
predominant in the nervous system [43]. 
Many studies have been conducted to shine a light on the importance of 
microRNAs in the heart. For example, it has been demonstrated that in zebrafish 
miR-138 is fundamental for the correct development of ventricles and for 
cardiomyocytes maturation. The loss of miR-138 leads to the expression in 
ventricular region of the genes whose expression is normally restricted to the 
atrio-ventricular valve region, and it induces a block of the ventricular 
cardiomyocyte differentiation [44]. 
Other studies have established that albeit miR-208, miR-145/miR-143 are 
abundant in the heart and they play an important role in the cardiomyocytes 
biology, the disruption of their  function do not induce a pathological phenotype 
during cardiac development in mice.  
The importance of miRNAs during cardiac development is confirmed by recent 
evidences. 
In a mouse model, the inactivation of Dicer in cardiac precursor cells was lethal 
during embryogenesis at E12.5 [45], and mice KO for DGCR8 developed a 
dilated cardiomyopathy, died of heart deficiency in less than 31 days, and 
expression levels of miR-1, miR-133 and miR-208, that are cardiac specific, 
noticeably decreased [46]. 
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Moreover, a study performed in 2007 by Ikeda and colleagues showed the 
expression of which microRNAs was altered in cardiac diseases; for example in 
dilated cardiomyopathy (DCM), in ischemic cardiomyopathy (ICM), and in aortic 
stenosis (AS), the expression levels of miR-1 are decreased whereas miR-214 
levels are strongly increased. Furthermore, changes in miRNA levels are not 
overlapping; this suggests that there is a distinct expression pattern of miRNA in 
each cardiac disease [47]. 
 
1.3 Cardiac Progenitor cells 
 
In the past years the general belief about heart has been that heart was a terminally 
differentiated postmitotic organ where the number of cardiomyocytes was 
established at birth and persisted during the life span of the organ. Moreover, the 
typical cardiac weight gain that occurs during hypertrophy was considered 
dependent from a rearrange of cytoplasmic organization of cardiomyocytes that 
grown in volume. However, in the last few years this general belief has been 
disavowed, in fact several evidences suggest that heart is in continuous turnover 
and has intrinsic regenerative potential. Mitotic cells have been found in normal 
and pathological hearts [48] and, afterwards, cardiac precursor or stem cells inside 
stem niches of the adult myocardium have been identified [49], [50]. A cardiac 
stem cell (CSC) has specific features: it is self-renewing (able to maintain the 
undifferentiated state even after many cell cycles), clonogenic (able to expand in 
culture after plating 1 cell per well), and multipotent that is the ability of 
differentiating into the three main cardiac lineages: myocytes, smooth muscle 
cells (SMC), and endothelial cells (EC). On the other hand, a progenitor cell is an 
immature committed proliferating cell able to differentiate into only one of the 
three above-mentioned lineages (myocyte or SMC or EC). Actually, there are still 
no markers that can distinguish a stem from a progenitor cell [51].  
The discovery of c-Kit-positive cardiac stem cells, that live in the heart and can 
differentiate into cardiac cell lineage, has definitely changed the knowledge about 
myocardial biology. However, the acceptance of the shift in ancient paradigm has 
been problematic and subjected to criticism. In fact, myocyte death is a normal 
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event that occurs during human heart diseases; in order to maintain heart vitality, 
myocyte death has to be accompanied by myocyte regeneration: this is the 
principle of homeostasis [52]. Moreover, the identification of CSCs has generated 
several doubts about their role in spontaneous cardiac regeneration after damage. 
As it is known, the physiological consequences of myocardium infarction are scar 
tissue formation and loss of mass and contractile function. The fact that resident 
human CSCs have limitations in reconstructing cardiomyocytes after infarction 
(this event is considered as the proof that heart is a post-mitotic organ terminally 
differentiated) [53] could be explained thinking that CSCs, which are present 
throughout the infarcted myocardium, die by apoptosis and necrosis as the other 
cells during heart failure [54]. 
 
1.3.1 Cardiac Stem Cell classes 
 
After the discovery of c-Kit-positive CSCs, different classes of progenitor cells 
have been described as ISL1-positive cells, side population progenitors, Sca-1-
positive cells and epicardial progenitors. All of them have been considered as 
distinct CSC classes (Figure 5). However, the unusual number of CSC categories 
clashes with the features of all self-renewing organ in which a single tissue-
specific adult stem cell has been found [54]. 
 
1.3.1.1 C-Kit-positive cells 
 
C-Kit-positive CSCs have been described, in rodent, for the first time 9 years ago, 
by Beltrami and colleagues, as cells with typical features of stem cells 
(clonogenic, able to divide symmetrically and asymmetrically in vitro and 
differentiate into myocyte, SMC or EC) [55]. In vivo, c-Kit+ -CSCs seem to be 
able to partly regenerate the infarcted myocardium differentiating in 
cardiomyocytes with mechanical and electric properties of functionally competent 
cells and ameliorating the performance of damaged heart [54]. 
C-Kit-positive primitive cells have been found also within spherical aggregates, 
called cardiospheres, formed afterwards cardiac surgical biopsy specimens 
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culture; these cells have been demonstrated to be positive also to CD105 that is 
regulatory component of the transforming growth factor-β receptor complex 
important in angiogenesis and hematopoiesis. Cardiospheres contain also 
differentiating cells, which express myocytes protein and connexin-43, and  an 
outer layer of mesenchymal stromal cells [56]. 
The localization of c-Kit positive cells have been also investigated in human adult 
heart in normal and pathological conditions. A study performed in 2008 showed 
that the number of c-Kit positive cells is increased in pathological hearts and they 
are more numerous in the subepicardium rather than in the myocardium; the 
authors also found that the subepicardium is strongly positive to laminin-1 which 
is typical of developing heart, suggesting that activation of regeneration is 
occurring in the myocardium  [57]. 
C-Kit-positive cells have been characterized by the expression of membrane, 
cytoplasmic and nuclear markers, and many studies reported that cardiac 
precursor cells express on their surface two main antigens: stem cell factor 
receptor (c-Kit or CD117) and Stem cell antigen 1 (Sca-1). The expression of 
these markers is not univocal: one of these antigens can be expressed alone or in 
combination with the other [58].  
 
1.3.1.2 Islet-1 positive cells 
 
An interesting study performed in 2005 by Laugwitz and colleagues, revealed that 
mammalian heart harbors progenitor cells which are positive to Isl-1. These cells 
have been considered to represent the authentic, endogenous cardiac progenitor 
cells because they display an highly efficient conversion to a mature cardiac 
phenotype with stable expression of cardiac markers [59]. Since Isl-1 is a 
transcription factor associated with the commitment to the myocyte lineage of 
cardiac cells that have lost their undifferentiated stem cell fate, some authors 
disavowed the idea that Isl-1-positive cells are cardiac precursors; they observed 
that Isl-1 expression is restricted to the embryonic and fetal hearts and that Isl-1 -
positive cells do not have the typical traits of stem cells [60].  
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However, tracing studies performed to investigate the relevance of Isl-1 -positive 
cells to myocardial regeneration, led to the evidence that few myocytes, SMCs 
and vascular ECs originated from Isl-1-positive cells [61]. 
 
1.3.1.3 Side population cells 
 
Side population (SP) cells have been described for the first time as cells able to 
expel toxic compounds and dye through an ATP-binding cassette transporter, 
Bcrp1 [62]. These cells have been characterized for the expression of several stem 
markers and they resulted to be Sca1high, c-Kitlow, CD34low, and CD45low [63].  
However, it has been observed that only the Sca1-positive CD31-negative subset 
of cardiac SP cells was characterized by a high cardiomyogenic potential [64]. 
 
1.3.1.4 Sca-1-positive cells 
 
Sca-1-positive progenitor cells represent a little part of the heart, but after 
oxytocin treatment they express cardiac transcription factors and contractile 
proteins organized in sarcomeric structures [65]. Moreover, it has been shown that 
transplantation of sheets of Sca-1-positive cells over the necrotic area of the heart 
after infarction prevents negative cardiac remodeling and improves cardiac 
function also through the release of humoral factors which facilitate engraftment 
and migration of CPCs from cell sheets into host myocardium [66]. 
 
1.3.1.5 Epicardial progenitors 
 
A pool of epicardial c-Kit-positive progenitor cells has been found in the human 
heart. It seems that they increase their number in hearts with chronic ischemic 
cardiomyopathy, and this increase is more evident in the subepicardial space than 
in the myocardium [57]. Moreover, these cells are able to migrate from the 
epicardium to the infarcted area where proliferate and differentiate into 
cardiomyocytes, endothelial cells and smooth muscle cells [67]. 
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Figure 5. Cardiac progenitor cells classes. Schematic representation of population of 
cardiac-derived progenitor cells [54]. 
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1.4 MiRNAs and stem cells 
 
Increasing evidences suggest that miRNAs are also involved in regulating cell 
renewal and differentiation. Several studies have  demonstrated that the transition 
from the stemness state toward the differentiated one is regulated by epigenetic 
mechanisms as chromatin remodeling and changes in DNA and histone 
modifications [68]. Since microRNAs are considered epigenetic modulators of 
mRNA degradation and protein translation, the idea that they can regulate stem 
cell maintenance and induce cell fate decision is increasingly spreading [68]. 
Several evidences demonstrate that microRNAs tightly control ESC self-renewal 
and differentiation state. Experiments of Dicer or DGC8 deletion, performed in 
mouse and human embryonic stem cells, confirmed a role of miRNAs in 
differentiation: the global loss of microRNAs resulted in proliferation and 
differentiation defects of embryonic stem cells [69].  Other studies identified 
specific sets of miRs, like miR-290 family and miR-302 family, as “embryonic 
stem cell-cell cycle regulating”  because they repress key regulators of the cell 
cycle to ensure a rapid G1-S transition [70]. After induction of ESC 
differentiation, other microRNAs have been identified as repressors of 
pluripotency: miR-134, miR-296 and miR-470, repress factors responsible of 
pluripotency as Nanog, Oct-4 and Sox2, allowing the acquisition of differentiated 
phenotype [71]. 
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Figure 6. MicroRNAs as key factors in self-renewal and differentiation [68] 
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1.5 MiR-1 and miR-133: the celebrities of the heart, development and 
differentiation 
 
MiR-1 and miR-133 are encoded by a duplicated locus in the mammalian 
genome. They are expressed by a cluster called miR-1-1/miR-133a-2 on the 
chromosome 2, and by a cluster called miR-1-2/miR-133a-1 on the chromosome 
18. However, miR-1-1 and miR-1-2, and miR-133a-1 and miR-133a-2, originated 
from different loci, have the same sequence [72]. Mi-206/miR-133b cluster is 
transcribed from a non-coding region on the chromosome 1. MiR-206 is skeletal 
muscle-specific and it shares with miR-1 the same seed sequence, but they differ 
for 4 nucleotides in the 3’-end. Mir-133b has the same seed sequence of miR-
133a-1 and miR-133a-2, and it differs just for one nucleotide in 3’end [72].  
MiR-1 is highly conserved among species: comparison of genomic sequences 
across species revealed that a 4.6 kilobase (kb) and 10.7 kb genomic region 
around miR-1-1 and miR-1-2, respectively, was conserved between human and 
mouse. Deletion analysis have shown that the minimum region for the 
transcription of miR-1-1 is 2.6 kb long, and that for the transcription of miR-1-2 is 
just 0.35 kb long. Within these regions there are several cis elements conserved 
between human and mouse that represented potential binding sites for the 
essential cardiac transcription factors Mef2, SRF, Nkx2.5 and Gata4 [73]. 
Mutation of the miR-1-1 SRF site abolished miR-1 expression in the heart. This 
finding confirmed that the presence of miR-1 is tightly dependent on SRF  [73]. 
Since miR-133 is located on the same locus of miR-1, it is also under the SRF 
control; moreover, miR-133 inhibits the expression of SRF through a negative 
regulating loop [74], [75]. 
Several studies have been performed to understand the miRNA role during 
cardiac development. It has been demonstrated that the miR-133a-1/miR-1-2 and 
miR-133a-2/miR-1-1 genes are expressed throughout the ventricular myocardium 
and interventricular septum from E8.5 until adulthood [73], [76]. 
Deletion experiments have highlighted on the importance of miRNAs in cardiac 
maturation. For example, in mouse, deletion of the gene coding for miR-1-2 or for 
miR-133 leads to alterations during cardiogenesis like the failure of ventricular 
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septation that results in death within few hours after birth [45], [77]. Both miR-1-
1 and miR-1-2 are more expressed in the outflow tract of the heart which derives 
from the secondary heart field. It has also been seen that miR-1 is fundamental for 
cardiomyocytes differentiation, thus it has anti-proliferation effects, in fact miR-1 
overexpression causes the loss of cardiomyocytes and cardiac hypoplasia which is 
lethal at E13.5. This event is due to the miR-1-mediated repression of Hand2, an 
important transcription factor involved in cardiomyocytes proliferation [73]. 
Experiments of deletion have shown that ≈ 50% of null mice for one of two loci 
of miR-1 dies from ventricular-septal defects (VSDs) between late embryogenesis 
and birth,  while a subset of mutant mice can survive to adulthood showing 
electrophysiological defects. On the other hand, complete ablation of miR-133 via 
double gene knockout induces cardiac defects during embryogenesis, and death 
one day after birth (P1 stage) showing dilated atria, and enlarged, engorged with 
blood, and containing thrombi hearts [77]. This suggests the occurrence of defect 
in cardiac contractility. 
A study carried in 2009 showed that small amounts of mature miR-1 and miR-133 
were present in mouse undifferentiated embryonic stem cells and that expression 
levels of these miRNAs increased after the induction of differentiation [78].  
MiR-1 and miR-133 have been identified as the most important regulators of 
muscle proliferation and differentiation [74]. In vitro studies have demonstrated 
that expression levels of miR-1 increase after the induction of  cardiac 
differentiation in mouse and human embryonic stem cell-derived cardiomyocytes; 
moreover, the increased expression levels of miR-499 have been observed [79], 
[80]. Sluijter and colleagues have demonstrated that overexpression of miR-1 or 
miR-499 promotes early occurrence of spontaneous beating areas after 
differentiation of cardiomyocyte progenitor cells (CMPCs); furthermore, they 
have shown that miR-1 overexpression in CMPCs results in a reduction in 
proliferative rate and that the overexpression of miR-499 leads to an increase in 
the expression of cardiac transcription factors responsible of cardiac 
differentiation; on the other hand, the inhibition of miR-499 inhibits cardiac 
differentiation [79]. Although miR-1 and miR-133 are localized on the same 
chromosomal locus, they have different biological roles. A study performed in 
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2009 revealed that miR-133 represses the expression of cardiac markers in the 
mouse and embryonic stem cells, inducing proliferation [78]. The promotion of 
myocytes proliferation miR-133-mediated has been proposed to occur by 
repressing serum response factor  (SRF) [75]; in contrast, in a more recent paper 
the authors found that the total ablation of miR-133 lead to an excessive 
cardiomyocyte proliferation, indicating that miR-133 functions as an inhibitor of 
cardiomyocyte proliferation; given that, the authors suggest that SRF can function 
as either a positive or negative regulator of cardiomyocyte proliferation and 
differentiation and the influence of miR-133a on downstream functions of SRF 
may vary depending on cofactor availability and extracellular signaling [77]. 
In summary, miR-1/miR-133 cluster is one of the main regulators of proliferation 
and differentiation of cardiac precursors. All the evidences mentioned above 
suggest that microRNAs play a fundamental role in regulating cell renewal and 
differentiation. Some authors have proposed that miRs are involved in fine control 
rather than in establish “on/off” decisions [68]. 
Since several studies suggest that overexpression of certain miRs promotes 
lineage commitment of stem cells, studying of these miRs could be useful for 
stimulation of in vitro and in vitro cell fate decision [68]. 
  
1.6 Heart regeneration 
 
Heart is the one of the least regenerative organs in the body, thus for many years 
the question, which scientists have tried to answer to, was about whether there is 
actually no regeneration or whether it occurs at low rate. Anyway, the field of 
cardiac regeneration is very important to investigate because myocardial 
infarction in few hours can wipe out 25% of 2-4 billion cardiomyocytes that 
compose the human left [81]. Moreover, hypertension or valvular heart diseases 
kill cardiomyocytes slowly over many years and ageing causes the loss of ≈ 1 g of 
myocardium (that corresponds to 20 million cardiomyocytes) per year in absence 
of specific cardiac diseases [82], [83]. 
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1.6.1 Heart regeneration in Zebrafish 
 
Unlike humans, many amphibia and fish are able to regenerate limbs and internal 
organs after injury. Recently, it has been found that, after amputation, the apex of 
zebrafish heart can completely regenerate by de novo heart tissue rather than scar 
tissue [84]. 
To investigate which kind of cardiac cells are involved in heart regeneration, 
genetic fate-mapping studies have been performed. Through the creation of 
transgenic zebrafish, employing the drug-induced Cre/lox system, it has been 
demonstrated that heart regeneration is principally mediated by the proliferation 
of pre-existing cardiomyocytes, rather than by the generation of new ones from 
stem cells. In the same work, the authors showed that proliferating 
cardiomyocytes undergo limited dediffertiantion disassembling their sarcomeric 
apparatus, detaching from  one another and expressing regulators of cell-cycle 
progression [85]. 
 
1.6.2 Heart regeneration in rodents 
 
Postnatal mammalian hearts show a lower capacity to regenerate than zebrafish 
hearts, but cardiomyocytes renewal during ageing and diseases occurs, even if 
with a lower rate.  
Several studies, similar to those conducted in zebrafish model, have been 
performed in order to establish whether progenitor cells contribute to 
cardiomyocyte renewal or whether cardiac regeneration depends on proliferation 
of existing cardiomyocytes. Through a genetic fate-mapping study, Hsieh and 
colleagues have observed that the limited endogenous reparative mechanisms 
depended on progenitor cells-mediated regeneration rather than on replacement by 
cardiomyocytes proliferation [86]. 
Moreover, a more recent study carried out by Porrello and colleagues in 2011, has 
reported that, after resecting the left ventricular apex of one-day-old neonatal 
mice, a brisk regenerative response occured; furthermore, they have observed that 
this regenerative capacity was not present in seven-day-old mice and, using the 
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genetic fate-mapping approach, they have demonstrated that cardiac regeneration 
depended on pre-existing cardiomyocytes, as in zebrafish heart. The authors have 
proposed that the strong decrease of age-related regenerative capacity of the 
mouse heart is related to the reduction of cell-cycle [87]. 
The high regenerative capacity of adult zebrafish heart is due to its anatomical  
organization. In comparison with the four-chambered and double-circulation 
mammalian heart that works at high pressure, the fish heart is characterized by 
two chambers and single-circulation and thus it shows a simpler organization. The 
adult zebrafish heart is anatomically comparable to the embryonic mammalian 
heart before septation. There are also many differences in cardiomyocytes 
features: mammalian cardiomyocytes withdraw from the cell cycle and become 
bi-nucleate shortly after birth [88], while zebrafish cardiomyocytes are 
mononucleated and they retain proliferative potential throughout life. So, given 
the similarities between the adult zebrafish heart and the immature mammalian 
heart, some researchers have hypothesized that the mechanism that is on the base 
of cardiac regeneration in fish is conserved in neonatal mammalian heart [87]. 
 
1.7 Adult stem cells and biomaterials for myocardial regeneration 
 
According to the general consent, cardiac stem cells reside in the mammalian  
hearts and they can probably adopt the cardiac fate. A spontaneous question that 
arises is: why do not cardiac stem cells work better than they do in regenerating 
myocardium after injury? 
As it is known, cardiac cells strongly interact with the extracellular matrix (ECM) 
which is an essential component of the functional myocardium. ECM contains 
growth signals for adult myocytes, as well as mitosis, growth, differentiation and 
migration signals for stem and progenitor cells [89].  
In the most of the studies about cardiac regeneration, the injection in the damaged 
heart of  many types of stem cells have shown to ameliorate cardiac function but 
they have a low survival rate after transplantation [90]. A plausible explanation is 
that cardiac stem cells do not receive proper “instructions”, like signals for 
recruitment, activation or maturation, to accomplish cardiac regeneration. Some 
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reports demonstrated that after myocardium infarction, new cardiomyocytes are 
produced in the border region of the infarcted area but not in the middle of the 
damaged zone [86]. This zonal selectivity can be explained by the fact that in the 
border region of the infarcted area there are many capillaries that can assure the 
proper perfusion and, moreover, the viable myocardium and the ECM provide 
certain fundamental signals that are necessary to stimulate  the regeneration [91]. 
In the last few years the strategy used by scientists to support cardiac regeneration 
is the employment of biomaterials to deliver these signals to transplanted stem 
cells. Since most stem cells are small cells, they leave within few minutes when 
injected in the infarcted area; for this reason biomaterials have been demonstrated 
to play a supporting role in maintaining of cells in loco. 
 
1.7.1 Biomaterials 
 
A biomaterial is defined as “[…] a substance that has been engineered to take a 
form which, alone or as a part of a complex system, is used to direct, by control  
of interactions with components of living systems, the course of any therapeutic or 
diagnostic procedure […]” [92]. The perfect biomaterial used in tissue 
regeneration should have properties of the extracellular matrix, including passive 
mechanical properties, signals for cell attachment, proliferation and 
differentiation. It should degrade without toxic metabolites production and, 
importantly, it should not give rise to a foreign body reaction and inflammatory 
response. Moreover, after implantation, biomaterials should last long enough to 
allow cell integration but, on the other hand, not too long to interfere with 
physiological coupling between differentiated cells [93].  
Biomaterials used for tissue regeneration can be natural polymers, as matrigel, 
collagen, fibrin and synthetic polymers, as polylactic acid, polyglycolic acid and 
copolymers. Natural polymers can be directly extracted from animals, plants and 
human tissues, thus, they show good biocompatibility and low toxicity [94]. 
Matrigel is a protein preparation extracted from Engelbreth-Holm-Swarm mouse 
sarcoma. It is composed by laminin, collagen IV, heparin sulfate proteoglycan and 
entactin [95]. Since matrigel is extracted from living cells, it contains many 
32 
 
growth factors and so it could be used as an injectable hydrogel for delivery of 
stem cells to cardiac tissue. However, since it derives from tumor cells, it would 
not be appropriate for clinical applications [91]. 
Collagen is an ubiquitous extracellular matrix protein. It has a long, rigid triple-
stranded helical structure which provides mechanical support and good 
environment for cell distribution and capillary formation and, moreover, its 
turnover is a fundamental factor in scar tissue formation and cardiac remodeling 
after infarct [94], [91]. Thus, collagen is very commonly used as substrate for 
three-dimensional in vitro cell culture and for in vivo tissue regeneration 
applications, because it is a nontoxic, nonimmunogenic and biodegradable 
compound. 
Fibrin is a fibrous protein involved, with fibrinogen and thrombin, in blood 
clotting. It is easily available and, for this reason, is widely employed in clinical 
applications. Fibrin has been demonstrated to be used as an injectable biomaterial 
to deliver stem cells to the heart after MI [96] or for the construction of a patch for 
epicardial applications [97].  
Although synthetic polymers are less biocompatible than the natural ones, they are 
used as scaffold because their degradation rate can be adapted to each specific 
application choosing proper polymer with proper characteristics, as porosity, 
three-dimensional shape and general morphology and, also because they are easily 
processed [94]. The most used polymers as scaffold materials are poly lactic acid 
(PLA) and poly glycolic acid (PGA). They are widely employed in tissue 
regeneration  along with scaffolds to transplant cells. Because of their 
thermoplasticity, these polymers can be handle to form the proper shape using 
standard processing techniques. PGA has a simpler structure than PLA, but PLA 
is more hydrophobic and less crystallizable and, for this reason, it degrades slower 
than PGA. However, PLA dissolves easier in organic solvents [94]. Thus, they 
present pro and con. However, both of them are commonly used in clinical 
practice [98]. 
The challenge for cardiac regeneration after injury is to find the “perfect” 
biomaterial which provides the proper three-dimensional structure and the 
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appropriate environment for retention of stem cells after implantation in the 
damaged tissue and for delivery of survival and differentiation signals. 
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2. OBJECTIVE 
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The discovery of cardiac stem cells that regulate myocyte turnover has profoundly 
changed the knowledge of myocardial biology. This novel information imposes a 
reconsideration of the mechanisms involved in myocardial aging, cardiac 
hypertrophy and heart failure. Thus, the critical role that CSCs play in the 
restoration of myocardial mass and function, has been largely investigated, and 
the idea that cell therapy may constitute a great promise for the treatment of 
cardiovascular diseases has been widely spread. 
Various types of adult progenitor cells have been identified and, in several studies, 
they showed beneficial effects in cardiac repair. For this reason they might have a 
therapeutic potential even if the individual subtypes of adult progenitor cells may 
have advantages and limitations [99]. 
The most important goal of regenerative medicine for the cardiac tissue is to find 
the best stem cell and the best way to deliver stem cells into a damage 
myocardium, improving their homing, integration and survival.  
To achieve this purpose, the field of biomaterials has been extensively 
investigated because they can modulate the environment for implanted cells and 
enhance CSC function in the heart. Biomaterials can mimic or include naturally 
occurring extracellular matrix and instruct stem cell function in different ways: 
promoting angiogenesis, enhancing stem cell engraftment and differentiation, and 
accelerating electromechanical integration of transplanted cells [91]. 
However, stem cell function is also regulated by epigenetic factors as 
microRNAs. MiRNAs are small non-coding RNAs, which control gene 
expression by inducing mRNA degradation or by blocking mRNA translation. In 
the cardiovascular system miRNAs can regulate hypertrophy, apoptosis, and 
fibrosis [100]. Recently, it has been demonstrated that miRNAs play an important 
role in controlling stem cell maintenance and differentiation [68]. Thus, since 
several studies suggest that overexpression of certain miRs promotes lineage 
commitment of stem cells, the study of these miRs could be useful for stimulation 
of in vivo and in vitro cell fate decision [68]. 
According to current insights into the cardiac progenitor cells, in this project we 
focused our attention on the embryonic origin of these cells in the human heart, 
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and on the role of miRNAs during their embryonic and in vitro differentiation 
inside scaffolds. 
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3. MATERIAL AND 
METHODS 
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3.1 Human cardiac samples collection 
 
Cardiac tissue samples, comprising the endocardial, myocardial, and epicardial 
layers of the ventricles, were obtained by autopsy from embryos, foetuses, 
preterm infants, and term infants and collected, after written consent from the 
mother, in the Department of Human Pathology of the University of Messina, 
Italy. Gestational age of the foetuses ranged between 9 and 40 weeks, as shown in 
Table 3 and Table 4. Specifically, our cohort comprised 25 samples. The causes 
related to the death of the analysed foetuses and of the preterm and term infants 
are shown in Table 3 and Table 4. Autopsies and sample collections were carried 
out immediately after delivery with less than a 24-hour interval since foetal death 
had occurred. All samples were fixed in 10% formalin and embedded in paraffin 
for morphological diagnostic evaluation (haematoxylin/eosin) and 
immunohistochemistry. Staining was performed three times per sample. 
 
3.2 Immunohistochemistry 
 
Single immunohistochemistry was performed by a streptavidin-biotin complex 
method using LSAB2 kit (DAKO Co., Carpinteria, CA, USA). After 
deparaffination and rehydration, the tissue sections were incubated with the 
protein blocking agent (DAKO) for 10 min and the primary antibody for 1 h. We 
used the anti-Isl-1 antibody (1:200, rabbit polyclonal, AB5754, Chemicon Int., 
Millipore Corp., Billerica, MA). The linked primary antibody was detected with 
DAKO LSAB2 streptavidin-peroxidase system according to manufacturer’s 
instructions. 3-Amino-9-ethylcarbazole (AEC) was used as a chromogen, whereas 
haematoxylin was used as a light counterstain. 
Double immunohistochemistry was performed by a streptavidin-biotin complex 
for the goat polyclonal antibody (CD105) and labelled using polymer-alkalyne 
phosphatase (AP) for the rabbit polyclonal antibody (c-Kit). After deparaffination 
and rehydration the tissue sections were incubated with the Peroxidase Block 
solution (Vector Laboratories Inc., Burlingame, CA) for 5 min, washed in PBS for 
5 min, and incubated with the anti-CD105 goat polyclonal antibody (1:50, SC-
39 
 
19793, Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 30 min. After 
washing in PBS, sections were incubated with the biotinylated anti-goat 
secondary antibody (1:200, SC-2774, Santa Cruz Biotechnology Inc.) for 30 min, 
and washed again in PBS. For the antibody detection the streptavidin-HRP 
complex (LSAB2 kit DAKO) was used for 10 min. Sections were then rinsed in 
PBS with 0.1% Tween 20 (T-PBS) for 5 min, and incubated with 3,3’-
Diaminobenzidine (DAB – Vector Laboratories) as the HRP-substrate. 
After the detection of the first antigen, sections were incubated with the 
Doublestain Block solution (Vector Laboratories) for 3 min, washed in T-PBS for 
5 min, and incubated with the anti-c-Kit rabbit polyclonal antibody (1:200, KAP-
TK005, Stressgen Bioreagents, Ann Arbor, MI) for 30 min. After washing with T-
PBS for 5 min, sections were incubated with a labelled polymer – AP secondary 
antibody (Vector Laboratories) for 30 min, and washed again. Fast red (Vector 
Laboratories) was used as the AP substrate for 5 min. Sections were then washed 
in tap water and counterstained with hematoxylin for 1 minute. DAKO Aqueous 
mounting medium was used. Each tissue section was analysed evaluating the 
percentage of positive cells in two paraffin embedded sections independently 
stained.  
 
3.3 Immunofluorescence 
 
After deparaffination and rehydration, tissue sections were blocked with 5% BSA 
in PBS for 30 minutes and incubated with the first primary antibody overnight, 
one night for each antibody (1:50, anti-c-Kit, KAP-TK005, Stressgen Bioreagents; 
1:50, anti-Isl-1, goat polyclonal, SC-23590, Santa Cruz Biotechnology Inc.). After 
washing with PBS, cells were further incubated with fluorescent secondary 
antibodies 1 hour at room temperature (1:50, TRITC-conjugated anti-rabbit 
secondary antibody, T5268, Sigma-Aldrich, St. Louis, MO; 1:50 FITC-conjugated 
donkey anti-goat secondary antibody, SC-2024, Santa Cruz Biotechnology Inc.). 
In single immunofluorescence experiments nuclei were stained 10 minutes with 
10 µg/ml Hoechst33342 staining in PBS (Invitrogen Corp., Carlsbad, CA). In 
confocal experiments nuclei were stained 15 minutes with 1 µM Toto-3 staining 
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in PBS (T3604, Invitrogen Corp.). To avoid cross-reactions, sections were 
incubated with goat-anti-Isl-1 first and with rabbit anti-c-Kit after, and with 
donkey anti-goat first and goat anti-rabbit after, in four different incubations.  
To avoid autofluorescence of paraffin/formalin embedded sections, the samples 
were incubated in 0.1% Sudan Black in 70% ethanol for 5 minutes after nuclei 
staining. For imaging they were both used a Zeiss LSM5 Exciter Laser Scanning 
Confocal Microscope and a Leica CTR5000 fluorescent microscope. During 
confocal microscope observations all parameters for picture acquisition were kept 
the same and automatically saved. 
 
3.4 In situ hybridization of human cardiac samples 
 
In situ hybridization experiments were performed using DIG-labeled 
miRCURY™ detection probes (Exiqon). After section deparaffination by xylene 
at 56°C for 20 minutes, sections were rehydrated with decreasing ethanol scale 
and treated with proteinase K 10 µg/ml at 37°C for 5 minutes in order to open 
holes on the tissue sections to let probes recognize the complementary sequence; 
after treatment  with 0.2% glycin in PBS for 30 seconds and washings in PBS, 
sections were fixed with 4% Paraformaldehyde (PFA)  for 10 minutes. 
Afterwards, sections were pre-hybridized for 2 hours with pre-hybridization 
buffer [50% formamide (Sigma-Aldrich), SSC 5x, 0.1% Tween, citric acid 9.2 
mM for adjustment to pH6, Heparin 50 µg/ml, yeast RNA (Applied Biosystem) 
500 µg/ml] in a chamber humidified with SSC 5x and 50% formamide. Slices 
were incubated overnight with DIG-conjugated  probes for dre-miR-133a, dre-
miR-1, U6, scramble-miR (pre-designed miRCURY LNA detection probes 5’-
DIG; Exiqon) (Table 1) diluted up to 20 nM in hybridization buffer, at 53°C. The 
day after, tissues were rinsed in SSC 2x at 53°C, 3 times in 50% formamide and 
SSC 2x at 53°C for 30 minutes and finally 5 times in T-PBS at room temperature. 
For the immunological detection of the DIG-labeled probe, slices were first 
treated for 1 hours at room temperature with the blocking buffer [2% sheep serum 
(Sigma-Aldrich Srl), 2mg/mL BSA in T-PBS] and then incubated over night at 
4°C with antibody anti-DIG-AP Fab fragments (Roche Diagnostics, Germany) 
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diluted 1:200 in blocking buffer. After washing in T-PBS, tissues were rinsed with 
AP buffer (Tris HCl 100 mM, MgCl2 50 mM, NaCl 100 mM, 0.1% Tween 20, 
pH9.5) and then treated for the color reaction with BCIP/NBT Color Development 
Substrate (Promega, Madison, WI, USA) [45 µl 75vmg/ml NBT, 35µl 50vmg/ml 
BCIP-phosphate, 2.4 mg Levamisole (DBA Italia) in 10 ml AP buffer] for 48 
hours. Tissue observation was performed with a Leica light microscope DM5000. 
Almost all solutions were RNase free. 
 
 
 
Table 1. LNA enhanced oligonucleotides sequences 
Probe Name Probe Sequence to 5'-3' T(m)* 
dre-miR-133° /5DigN/CAGCTGGTTGAAGGGGACCAAA 80 
dre-miR-1 /5DigN/ATACATACTTCTTTACATTCCA 63 
U6, hsa/mmu/rno /5DigN/CACGAATTTGCGTGTCATCCTT 75 
Scramble /5DigN/GTGTAACACGTCTATACGCCCA 78 
*The LNA Tm was calculated using the tool accessible at www.exiqon.com 
 
 
 
 
3.5 Statistical analysis 
 
Data are shown as mean values and the standard deviation has been calculated. 
The hypothesis that the number of Isl-1+ cells per mm2 varied with the gestational 
age was tested using a t-test of dependent samples (P<0.05). The hypothesis that 
there was a linear correlation between the gestational age of the foetuses and the 
number of Isl-1+ cells per mm2 was tested using the Pearson coefficient (P<0.05). 
For the statistical analysis it was used the STATISTICA 6.0 software (StatSoft 
Italia srl, Italy). 
In order to have a kinetic profile of miRNA expression in human hearts at 
different gestational ages, the signal was quantified. Images were first processed 
by adobe Photoshop CS5 in order to abolish the noise and then analyzed by 
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ImageJ Free software (NIH, Bethesda, MD) (http://rsb.info.nih.gov/ij/). Statistical 
analysis was performed using the T-test for dependent variables (P<0.05). 
 
3.6 Progenitor Cells Isolation and purification 
 
Adult Sprague–Dawley rats (up to 8 months-old), ≈ 300 g in weight, were 
anesthetized with: isofluoran vaporized, zoletin 20 0.20 mg/kg IM, medetomidine 
0.25 mg/kg IM, atropine 0.0025 mg/kg SC. Hearts were excised still beating and 
put in Hank’s Balanced Salt Solution (HBSS) (Sigma-Aldrich) with collagenase 
type II 200 U/ml (Gibco; Invitrogen Corp., Carlsbad, CA), calcium chloride 3 
mmol/l and  a double dose of pen/strep (Lonza). Hearts were then cut separating 
atria from ventricles; each ventricle has been cut into two small pieces which have 
been put in a fresh solution of HBSS and collagenase type II as described above. 
To allow the activation of the enzyme, pieces were incubated at 37°C in a rotating 
incubator. After that, most of the solution was centrifuged at 500 rpm for 5 
minutes, while pieces remained in the rotating incubator at 37°C. These passages 
were repeated 10 times. The first fraction of pellets, obtained after the first five 
centrifugations, was discarded. The second one, got after the second five 
centrifugations, was filtrated with nylon net filters (Millipore) whose diameter 
was 80 µm, and then collected and plated in 75 cm2 flasks with M-199 medium 
(BD Biosciences, Franklyn Lakes, NJ) supplemented with 20% Fetal Bovine 
Serum (FBS; Biolife Italiana S.r.l., Milano, Italy), fungizone 3mg/ml, 
streptomycin 300mg/ml, and penicillin 300 U/ml. 
This method of tissue digestion allows a rapid recovery of cells with a shorter 
exposure of the isolated cells to the collagenase solution. 
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3.7 Flow cytometryc analysis  
 
After detaching from flasks, cells were counted and placed into FACS tubes 
(2x105 cells/sample). Initially, cells were washed in PBS and then fixed in cold 
methanol on ice for 20 minutes. After washing, cells were blocked with 
incubation buffer (9 PBS : 1 M-199 + 10% FBS) at room temperature for 15 
minutes. Cells were incubated with primary antibodies diluted 1:200 in incubation 
buffer for 45 minutes at room temperature [anti-c-Kit, KAP-TK005, (Stressgen 
Bioreagents, Ann Arbor, MI, USA); anti-Ly-6A/E (Sca-1), clone E13-161.7ne V 
(Santa Cruz Biotechnology, Inc); anti-MDR1, SC-71557 (Santa Cruz 
Biotechnology, Inc)], rinsed twice in PBS and incubated with secondary 
antibodies diluted 1:200 in incubation buffer for 45 minutes at room temperature 
in the dark. After two washes in PBS, cells were analyzed with a FACSCalibur 
Flow Cytometer (BD Biosciences). The unstained sample was used to calibrate 
the analysis. 
 
3.8 Immunofluorescence on CPCs 
 
Cells cultured on poly-D-lysin (Sigma – Aldrich) coated chamber slides were 
fixed firstly with 4% PFA for 15 min and after with ice-cold methanol for 30 min. 
Antigen retrieval with 10 mM citrate buffer (pH 6.0) with 0.05% Tween 20 for 10 
min. After incubation with 5% Bovine Serum Albumin (Sigma – Aldrich) for 30 
min, cells were incubated with primary antibodies, diluted 1:50 in PBS, overnight 
at 4°C [anti-c-Kit, KAP-TK005, (Stressgen Bioreagents, Ann Arbor, MI, USA); 
anti-Ly-6A/E (Sca-1), clone E13-161.7ne V (Santa Cruz Biotechnology, Inc); 
anti-MDR1, SC-71557 (Santa Cruz Biotechnology, Inc)]. Primary antibody was 
detected with: 1:50, FITC-conjugated anti-goat secondary antibody (Sigma – 
Aldrich). Nuclei were stained 10 minutes with 10 µg/ml Hoechst33342 staining in 
PBS (Invitrogen Corp., Carlsbad, CA). Cells were observed using Leica CTR5000 
fluorescent microscope. 
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3.9 Tumorigenicity tests: in vitro and in vivo 
 
3.9.1 In vitro 
 
CPCs, the cell line VERO (negative control) and the cell line Hep-2 (positive 
control) were cultured in vitro into three different 75cm2 flasks (BD Biosciences). 
Later, each cell culture (1x105 cells) was inoculated in six-well plates containing 
the solid medium (MEM plus Agar Noble, BD Bioscience) and incubated at 37°C. 
They were observed at inverted microscope for 3 weeks. The number of colony 
forming units (CFU) were counted and compared to the control (Hep-2).  
 
3.9.2 In vivo 
 
Cardiac progenitor, VERO and Hep-2 cells were inoculated in vivo by intra-
cutaneous injection. Every cell type was injected in 10 Nude mice. Animals have 
been observed for 21 days and any new-formation of nodules in the injection area 
was check. The size and weight of the neoplasia were measured to evaluate the 
growth after 21 days. The test was considered valid if at least 9 mice  inoculated 
with the positive control  cells (Hep-2) produced a neoplasia. 
 
3.10 Cell seeding in 2D and 3D cultures 
 
For bi-dimensional cultures, cells were plated in 75 cm2 flasks, grown in presence 
of M-199 (BD Biosciences, Franklyn Lakes, NJ, USA) grow medium, 
supplemented with 20% FBS (Biolife Italiana), antibiotic-antimycotic solution 1x 
(Lonza), L-glutamine 1x (Gibco) for 21 days, as previously described [58]. 
For three-dimensional cultures, cells were cultured into the Open-pore Polylactic 
Acid (OPLA) scaffolds (BD Biosciences) and into customized Poly(d,l) Lactic 
Acid [P(d,l)LA] composite scaffolds: L150609N, L150609T, L150609U 
(synthesized with a porosity agent less than 224 µm), L070709A (synthesized 
with a porosity agent less than 150 µm), kindly provided by Biotech Laboratories 
(University of Trento).  
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Before cell seeding, customized scaffolds were sterilized with 96% ethanol for 1 
h. Thereafter, scaffolds were equilibrated with M-199 medium supplemented with 
20% FBS, and air dried. 
A mix of CSCs collagen type I rat tail (BD Biosciences) diluted 1:8 in M-199 
grow medium was prepared on ice. Small pieces of scaffolds were embedded with 
cells and collagen mix and kept for half-hour at 37° C inside inserts for 24-well 
plates (BD Biosciences); each insert contained  4x105cells. Then scaffolds were 
layered  with collagen I in M-199 (dilution 1:8) and kept at 37° C for 3 hours in 
order to allow the solidification of collagen I. Afterwards, inserts were filled with 
growth medium and left in incubator for 21 days changing medium every two 
days.  
 
3.10.1 P(d,l)LA scaffold microfabrication 
 
The porous, three-dimensional P(d,l)LA scaffolds were prepared, using a solvent 
cast particulate leaching technique. The polymer was first dissolved in (70:30 v/v) 
dichloromethane/dimethylformamide solvent and then poured into a glass Petri 
dish containing a sufficient amount of NaCl salt. The suspension was then dried 
under hood overnight and washed into water for three days in order to eliminate 
the residual solvent and the salt. The sponges obtained were frozen at -20°C and 
then lyophilized for 2 days. 
 
3.11 Transmission electron microscopy 
 
Three-dimensional cultures were grown in M-199 medium (Life Technologies) 
supplemented with 20% FBS (Life Technologies) for 21 days and then fixed 
twice. In the first step, scaffolds were fixed with 2.5% glutaraldehyde (Electron 
Microscopy Sciences), in 100 mM sodium cacodylate (Life Technologies) buffer 
(pH 7.4) for 30 min and rinsed 3 times with 100 Mm sodium cacodylate buffer. A 
second step of fixation was performed with 2% OsO4 (Electron Microscopy 
Sciences) in 100mM sodium cacodylate buffer. After fixation, samples were 
rinsed twice with 100 mM sodium cacodylate buffer (pH 7.4), and dehydrated 
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with ethanol (25%, 50%,70%,95% and 100%). After dehydration scaffolds were 
embedded into EPON resin (Electron Microscopy Sciences) with passages of 1:3 
of resin/70% ethanol, 3:1 resin/70% ethanol for 2 h, pure resin overnight, pure 
resin with 0.1 ml DMP-30 (EMS) for 3h before inclusion and for 65°C at 48 h. 
Semi-thin sections were prepared and stained with Methylene Blue (Sigma - 
Aldrich). 
 
3.12 RNA extraction and RT-PCR 
 
Total RNA from cell grown for 21 days in bi-dimensional and three-dimensional 
cultures was purified by using ChargeSwitch® Total RNA Cell Kit (Life 
Technologies Europe BV Kwartsweg, Bleiswijk, Netherlands), whereas total 
amount of RNA from cardiac tissue was extracted using QuickPrep Total RNA 
Extraction Kit (GE Healthcare Bio-Sciences Corp., Piscataway, USA). RNA from 
both extractions was quantified by Qubit® RNA Assay Kits (Life Technologies). 5 
ng total RNA per reaction was reverse-transcribed using ImProm-II Reverse 
Transciptase Kit (Promega Corporation, Madison, Wisconsin, USA) and GoTaq 
Flexi DNA Polymerase (Promega Corporation) following manufacturer’s 
instructions. cDNA was amplified using primers listed in Table 2. Beta-actin was 
used as a positive control. RT-PCR products were separated on 3% agarose gel. 
The gel was stained with SYBR SafeDNAgel stain (Life Technologies). 
ImageJ Free software (NIH, Bethesda, MD) (http://rsb.info.nih.gov/ij/) was used 
to obtain a numeric value for each band intensity (Mean intensity of color x 
Number of pixels). Values between 1 and 150,000 were considered +/-; values 
between 15,000 and 50,000 were considered +; values between 50,000 and 
120,000 were considered ++; values between 120,000 and 200,000 were 
considered +++; 0 was considered – (Table 3). 
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Table 2. Primers used for semiquantitative reverse-transcription-polymerase chain 
reaction 
 
Primers Nucleotide sequence 
Beta Actin Fw 5’- AGCCATGTACGTAGCCATCG-3’ Rv 5’ - CTCTGAGCTGTGGTGGTGAA-3’ 
Laminin Fw 5’- TGTAGTTCTGCAGCCATTCG-3’ Rv 5’-CATAGGGCTGGAAGCAAGAG-3’ 
Integrin alpha V Fw 5’-GCTGCCGTTGAGATAAGAGG-3’ Rv 5’-TGCCTTGCTGAATGAACTTG-3’ 
Integrin alpha 6 Fw 5’-GGTGACTTCAAAGCCTGCTC-3’ Rv 5’-AGC CAG ATC AAA AAC CAA GG-3’ 
Integrin alpha 7 Fw 5’-ACC TGT GCA CAC CGA TAT GA-3’ Rv 5’-GCA GAA CCC AAA TTG TTC GT-3’ 
Integrin beta 1 Fw 5’-GAA CAG CAA GGG TGA AGC TC-3’ Rv 5’-CAC AGT  TGT CAC GGC ACT CT-3’ 
Fibronectin 1 Fw 5’-GAAAGGCAACCAGCAGAGTC-3’ Rv 5’-CTGGAGTCAAGCCAGACACA-3’ 
ILK Fw 5’-AAGGTGCTGAAGGTTCGAGA-3’ Rv 5’-CAG TGT GTGT ATG AGG GTT GG-3’ 
FAK Fw 5’-CGT GAA GCC TTT TCA AGG AG-3’ Rv 5’-TCC ATC CTC ATC CGT TCT TC-3’ 
CgA Fw 5’-GCC ACC AAT ACC CAA TCA CC-3’ Rv 5’-CTT TAG GCC CAG CCT TCT CT-3’ 
Collagene V alpha Fw 5’-GGG TGC TAG ATC AGG AGC AG-3’ Rv 5’-ATG CCC ACT CCC TAA CAG TG-3’ 
Vitronectin Fw 5’-ACC CTG ATT ATC CCC GAA AC-3’ Rv 5’-CAA ACA CGG CTG ACA GAG AA-3’ 
eNOS Fw 5’-TGA CCC TCA CCG ATA CAA CA-3’ Rv 5’-CTG GCC TTC TGC TCA TTT TC -3’ 
Hsp90 Fw 5’-GATTGACATCATCCCCAACC-3’ Rv 5’-CTG CTC ATC ATC GTT GTG CT-3’ 
Troponin T2 Fw 5’-CGT GAG GAG GAG GAG AAC AG-3’ Rv 5’-CGG CCT CTA GGT TGT GGA TA-3’ 
Cardiac α MHC Fw 5’-CTG CTC AAG GGT CTG TGT CA-3’ Rv 5’-CGA ACA TGT GGT GGT TGA AG-3’ 
AKT Fw 5’-CAG CAT CGG TTC TTC CTC AG-3’ Rv 5’-AGA ACT GGG GGA AGT GTG TG-3’ 
Calmodulin Fw 5’-ACT GGG TCA GAA CCC AAC AG-3’ Rv 5’-CTT GAC CTG TCC GTC TCC AT-3’ 
Caveoli  3 Fw 5’-AGA CCA CTT TCA CCG TCT CC-3’ Rv 5’-GCTGATGCACTGGATCTCAA-3’    
CD73 Fw 5’-AGAGCAAACCAGCGATGACT-3’ Rv 5’-CATTTCTGAGGAGGGGATCA-3’ 
CD14 Fw 5’-CTTGTTGCTGTTGCCTTTGA-3’ Rv 5’-CGTGTCCACACGCTTTAGAA-3’ 
CD90 Fw 5’-CGAACTTCACCACCAAGGAT-3’ Rv 5’-AAGGAGAGGGAAAGCAGGAG-3’ 
CD19 Fw 5’-TAGGCAGTGGTGCTGTGTCC-3’ Rv 5’-TTCATAGGCCTCCCCTTCTT-3’ 
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3.13 RNA extraction and Q-RT-PCR for microRNA analysis 
 
Total RNA from cell grown for 21 days in bi-dimensional and three-dimensional 
cultures was purified using  miRCURY™ Isolation kit (Exiqon) according to 
manufacturer’s instructions. From each sample ≈ 90-150 ng/µl of RNA were 
collected.  
 
3.14 MicroRNA qRT-PCR service and data analysis 
 
Two samples of RNA, extracted using miRCURY™ Isolation kit (Exiqon) from 
CSCs grown for 21 days in 2D and 3D cultures (CSCs in a 3D collagen I matrix), 
were shipped on dry ice to Exiqon, Inc., which provided the service for RNA 
quality verification and microRNA qPCR as well as comprehensive analysis. 
After RNA quality control, 40 ng of RNA was reverse transcribed into cDNA 
using miRCURY LNA™ Universal RT microRNA PCR, Polyadenilation and 
cDNA synthesis kit (Exiqon). cDNA was diluted 50x and assayed in 10 µl PCR 
reactions and transferred to qPCR Rodent Panel I, preloaded with 384 primers. 
Rno-miR-423, rno-miR-103, rno-miR-191, U6 and RNU5G were used as 
reference genes. Negative controls excluding template from the reverse 
transcription reaction was performed and profiled like the samples. The 
amplification was performed in a LightCycler® 480 Real-Time PCR System 
(Roche). The amplification curves were analyzed using the Roche LC software, 
both for determination of Cp (by the 2nd derivative method) and for melting curve 
analysis. 
The amplification efficiency was calculated using algorithms similar to the 
LinReg software. All assays were inspected for distinct melting curves and the Tm 
was checked to be within known specifications for the assay. Furthermore, assays 
was detected with 5 Cp’s less than the negative control, and with Cp<37 was 
included in the data analysis. Data that did not pass these criteria were omitted 
from any further analysis. 
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4. Results 
 
 
 
 
 
50 
 
4.1 Localization of cardiac stem cells and study of the expression of miRNAs 
in human embryos and fetuses  
 
4.1.1 Expression of c-Kit on the membrane of cardiomyocytes of fetal hearts  
 
In order to investigate the localization of c-Kit-positive CPCs in human 
embryonic and fetal hearts, immunohistochemistry and immunofluorescence 
experiments were performed. As shown in Figure 7A-C and summarized in Table 
3, in samples from the 9th to the 17th gestational week, many interstitial and 
subepicardial cells and almost all cardiomyocytes expressed c-Kit receptor on 
their membrane. Even if more rarely, some c-Kit+ cells were found in samples at 
22nd gestational week. The presence of c-Kit receptor on the surface membrane of 
cardiomyocytes of the first and second gestational trimesters was confirmed by 
immunofluorescence experiments (Figure 8A, F). Panels B and C of the Figure 8 
show that in the only embryonic sample, at 9th week, there are some structures, 
similar to the primordial myocardium of the cardiac tube that  are clearly positive 
to c-Kit. Moreover, as shown in Figure 8D, clusters of c-Kit+ cells are present also 
in samples at 15th week of gestation. 
 
4.1.2 Immunolocalization of cardiac progenitor cells 
 
Different studies reported in literature have identified several cardiac progenitor 
cell populations; two of them have been described as double positive for c-Kit and 
CD105, in adult hearts [56] and as Isl-1-positive cell, in developing mammalian 
heart [59]. In order to localize separately the two populations in the human fetal 
heart, a double immunostaining for c-Kit and CD105, and a single 
immunostaining for Isl-1were performed. Results were summarized in Table 3 for 
c-Kit/CD105 and Table 4 for Isl-1. As shown in the panels E-F of Figure 7, 
interstitial c-Kit+/CD105+ cells appeared from the 17th gestational week and 
persisted after birth, with no differences between normal hearts and fetus with 
heart malformation (Table 3). Double positive cells were localized in the 
myocardium where many dividing cells were found (Figure 7F). Single positive 
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cells to c-Kit were identified  in the subepicardial space (Figure 7A) and in the 
myocardium (Figure 7C), while cells positive to CD105 were found in 
endocardium and endothelium as shown in Figure 1B; both of them compared 
from the 9th to the 16th gestational week. 
Right and left ventricles did not show any differences in the expression of Isl-1 
marker. As shown in Figure 7D and G, Isl-1+ cells were found in the myocardium 
and in the subendocardic space. Groups of Isl-1+ cells were sometimes visible, 
with a number ranging between 4.523±1.22 x 104 at the 14th gestational week and 
0.548±0.12 x 104 per mm2 in the post-natal age (Table 4, Figure 7 D,G). Statistical 
analysis, performed using the T-test for dependent variables, revealed that the 
decreasing number of Isl-1+ cells was significant and it depended on the 
gestational week. On the other hand, the number of Isl-1+ cells increased from the 
14th to the 16-19th gestational week and it remained constant between the 20th 
gestational week and the post-natal age. The Pearson coefficient (r=0.5; P=0.14) 
demonstrated that there was not a linear correlation between the gestational week 
and the number of cells per mm2. 
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Figure 7. Identification of interstitial c-Kit+/CD105+ and Isl-1+ cells in human fetal 
and infant hearts before (A-D) and after (E-G) the 17th gestational week.  
Immunostaining for c-Kit (Fast Red) (A-C) and CD105 (DAB) (B) in a 16-week fetal 
heart. E, F) c-Kit and CD105 double immunostaining in a preterm infant (36 weeks of 
gestation), E) and in a term infant (6-year-old child). F) Black arrows indicate double 
stained cells. D) Isl-1 (AEC) single immunostaining in a 14-week foetal heart; red 
arrows indicate Isl-1 positive cells. G) Isl-1 single immunostaining in a 21-week fetal 
heart. Double positive cells appeared deep red; red arrow indicate Isl-1 positive cells. 
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Figure 8. Expression of c-Kit and Isl-1 in embryonic and fetal hearts. A) Expression 
of c-Kit in a 16-week fetal heart. B, C) Expression of c-Kit in a 9-week human embryo. 
D –A cluster of c-Kit+ cells in a 15-week fetal heart. E) Co-localization of c-Kit+ and Isl-
1+ cells in a 14-week fetal heart; white arrows indicate cells double positive for Isl-1 and 
c- Kit. F) Confocal microscopy analysis of the expression of c-Kit and Isl-1 in the 
myocardium of a 16-week fetal heart. 
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Table 3. Clinical and morphological data and c-Kit/CD105 expression in 1 embryo, 12 
fetuses, 1 preterm infant and 1 term infant 
 
 
 
 
Table 4. Clinical and morphological data and number of Isl-1 positive cells per area 
(mm2) in 7 fetuses, 2 preterm infants and 1 term infant. 
 
 
 
 
 
 
55 
 
4.1.3 Co-localization of c-Kit+/Isl-1+ cells 
 
In order to investigate whether c-Kit and Isl-1 markers labeled different cell 
populations or not, their co-localization was evaluated by immunofluorescence 
experiments. It was found that all the interstitial subendocardial Isl-1+ cells were 
positive also for c-Kit (Figure 8E), while not all the cells positive for c-Kit were 
also positive for Isl-1 (Figure 9A). Moreover, almost all the cardiomyocytes were 
c-Kit-positive (Figure 8F). The co-localization of the expression of c-Kit and Isl-1 
on the same cell was confirmed by confocal microscopy (Figure 9B). 
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Figure 9. Co-localization of cells positive to c-Kit and Isl-1.  A) Three cells positive to 
c-Kit, of which only one is also positive to Isl-1. B) Confocal microscopy enlargement of 
an interstitial cell positive to both c-Kit and Isl-1 
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4.1.4 MicroRNA expression in human heart at different gestational ages 
 
In order to investigate how the expression levels of two of the most common 
expressed miRNAs in the heart, change during development, in situ hybridization 
experiments, using miR-1 and miR-133 probes, were performed. Samples from 
16th, 20th, 32nd week were analyzed. As shown in the panels A-F of figure 10, all 
the samples were positive for both of miRNAs with no appreciable variation 
among the different gestational ages, compared with controls (Figure 10G-H); 
nevertheless, analysis performed by the ImageJ Free software (NIH, Bethesda, 
MD) (http://rsb.info.nih.gov/ij/) revealed changes  in miR-133 expression levels 
but not in miR-1 expression levels. MiR-133 significantly increased at 20th 
gestational week and decreased at the 32nd week; on the other hand, miR-1 did not 
undergo significant variations (Figure 10I). A light increase in miR-133 
expression was observed in the bigger vessel of samples at 32nd gestational week 
(Figure 10J-K). 
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Figure 10. miR-1 and miR-133 expression in embryonic and fetal hearts by in situ 
hybridization. A-B-C) MiR-1 expression in 16-20-32-week fetal hearts; bar = 100µm D-
E-F) miR-133 expression in a 16-20-32 week fetal hearts; bar = 100µm. U6 positive 
control (G) and Scramble negative control (H); bar = 50µm. I) Graphic representation of 
the variation of miR-1 and miR-133 expression levels during the three different 
gestational week. J-K) miR-133 expression in big vessels of 32-week fetuses; bar = 
100µm (J) and 20µm (K). 
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4.2 Investigation on the role of miRNAs in cardiac stem cell in vitro 
differentiation 
 
4.2.1 Cardiac stem cell isolation and characterization 
 
Cardiac immature cells were isolated from adult rats using a differential adhesion 
method. Two weeks after cell isolation, a good amount of proliferating cells was 
obtained. Isolated cells were characterized by flow cytofluorimetric analysis and, 
as shown in Figure 12A, the fraction of c-Kit positive cells  varied from 61.0% to 
96.7% (mean 83.23 ± SD 19.3) as previously described [101], Sca-1 positive cells 
varied from 74.6% to 98.2% (mean 86.93%  ± 11.83), MDR-1 positive cells 
varied from 61.1% to 72.3% (mean 63.13% ± 5.68). The expression of the three-
markers was also confirmed by immunofluorescence analysis (Figure 12B-D). 
In order to investigate the tumorigenic capacity of isolated cells, specific in vivo 
and in vitro tests were performed. 7-10 days after the beginning of the in vitro 
tumorigenicity test, Hep-2 (positive control) started to replicate producing 
multicellular agglomerates, while the negative cells (VERO) showed atrophy. 
Both the in vitro and in vivo test revealed that CPCs: There were no evidences of 
tumors in the several organs analyzed in mice inoculated with VERO and cardiac 
progenitor cells (Figure 12). 
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Figure 11. Cardiac progenitor cell characterization. Cytofluorimetric analysis to 
evaluate the percent of c-Kit, Sca-1 and MDR-1 positivity (A). Immunofluorescence 
analysis to c-Kit (B), Sca-1 (C) and MDR-1 (D). Bar = 20µm. 
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Figure 6. Histological analysis of organs after CPC inoculation in mice. Organs of 
two different mice were analyzed (A-J and K-T). Bar = 200µm (A-E and K-O); bar = 20 
µm (F-J and P-T). 
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4.2.2 Cells in three-dimensional culture are partially differentiated in vitro: 
morphological evaluations 
 
In a previous study performed in our laboratory, scaffolds were used to study the 
differentiation potential of CPCs [58]. In order to understand which was the better 
condition for cell differentiation induction, three-dimensional cultures with BD 
OPLA scaffolds and customized P(d,l)LA scaffolds were performed. Morphologic 
features of CPC grown bi-dimensional culture are shown in Figure 13A; as 
displayed in the panel B of the Figure 13, cells were equally distributed inside the 
scaffolds and perfectly embedded in the scaffold matrix. 
CPCs were let grow into the scaffolds for 7, 14 and 21 days in their normal 
growing conditions; as shown in Figure 13C, after 21 days they expressed great 
amount of troponin T. Morphological analysis of semithin sections revealed that 
cells appeared huger and full with material similar to unorganized  sarcomeric or 
cytoskeletal proteins (Figure 13D). A more accurate TEM observation showed the 
presence of caveolae on the cell membrane (Figure 13E). 
Since 3D cultures were performed embedding cells in collagen I, in order to 
understand whether cell differentiation was depending on the presence of the 
three-dimensional structure offered by scaffold or not, CPCs were cultured for 21 
days in 3D matrix made by collagen I, without scaffolds. Interestingly, the 
cytoplasm appeared more granular and better organized suggesting a higher 
degree of differentiation (Figure 13F).  
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Figure 13. CSC partially differentiate in vitro inside porous scaffolds. Phase contrast 
image of isolated cells in 2D cultures (A) (bar = 100µm), ematoxilin/eosin staining of 
isolated cells cultured for 21 days inside BD OPLA scaffold (B), confocal scanning 
microscopy showing the expression of cardiac troponin T in 21 days 3D cultures inside 
OPLA scaffold (C), TEM image of panel E showing the cellular membrane, the 
cytoplasm and one caveola (D), methylene blue stained semi-thin section of 21 days 3D 
cultures inside BD OPLA scaffold (E). Methylene blue stained semi-thin section of 21 
days 3D cultures inside collagen I (F), P(d,l)LA-N scaffold with collagen I (G), inside 
P(d,l)LA-U scaffold with collagen I (H). Bar = 20 µm 
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4.2.3 Extracellular matrix molecules expression in bi-dimensional and three-
dimensional cultures 
 
The expression of extracellular matrix proteins and their receptors is essential for 
the proper development and for keeping myocardium functional. For this reason, 
we studied the expression levels of cardiac mRNAs encoding for some 
extracellular matrix proteins and their receptors, some downstream signal 
molecules, and structural proteins in CPCs cultured in bi and three-dimensional 
cultures by RT-PCR. 
As shown in Table 5, cells cultured for 21 days in commercial OPLA scaffolds 
show a low expression pattern of almost all considered genes compared with the 
expression pattern of cells cultured in customized P(d,l)LA scaffolds. On the other 
hand, although cells in three-dimensional scaffolds have been cultured in presence 
of collagen I, cells cultured in presence of collagen I without scaffolds show a 
bigger number of strongly expressed genes. Particularly, extracellular matrix 
proteins like laminin and fibronectin are more expressed in 3D-culture with 
collagen I compared to 3D-cultures with commercial and customized scaffold and 
2D-cultures; the same happens in the case of almost all the ECM receptors and 
downstream signaling molecules as integrin classes, AKT, ILK and FAK. 
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Table 5. Expression of ECM molecules and receptor, cardiac-specific genes by RT-PCR 
  
Rat 
cardiac 
tissue 
2D 
Culture 
Collagen I 
only 
Collagen I 
and BD  
Collagen I 
and  
P(d,l)LA-N 
Collagen I 
and 
P(d,l)LA-U  
Beta-actin +++ ++ +++ + ++ ++ 
Laminin + - ++ - - + 
Fibronectin + ++ +++ ++ +++ +++ 
Coll V alpha ++ - + + + - 
Vitronectin ++ - - - + - 
Integ alpha V + - +++ - ++ + 
Integ alpha 6 ++ - ++ + + + 
Integ alpha 7 ++ - ++ +/- + - 
Integ beta 1 ++ - +++ +/- ++ ++ 
ILK ++ - +++ + +++ ++ 
FAK + - +++ - + + 
AKT ++ + +++ - ++ ++ 
Calmodulin +++ +++ +++ +++ +++ +++ 
Cav3 +++ - +++ - + + 
CgA ++ - - - + - 
eNOS + - - - - - 
HSP90 +++ ++ +++ + ++ ++ 
Trop T2 +++ + +++ +++ + + 
Cardiac MHC +++ - - - - - 
 
 
Note: These data were obtained analyzing the gel bands with ImageJ to obtain a numeric 
value for each band intensity (Mean intensity of color x Number of pixels). Values 
between 1 and 150,000 were considered +/-; values between 15,000 and 50,000 were 
considered +; values between 50,000 and 120,000 were considered ++; values between 
120,000 and 200,000 were considered +++; 0 was considered -. 
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 4.2.4 The microRNA expression in bi and three-dimensional culture of CPCs 
 
In order to investigate the microRNA expression in CSCs grown in bi-
dimensional cultures and in three-dimensional collagen matrix, the microRNA q 
PCR service was performed by Exiqon (Vedbaek,  Denmark). The expression 
levels of 384 rat and mouse known microRNAs were checked. Raw data analysis 
reveals that the total number of expressed miRNAs was higher in cardiac stem 
cells grown in 3D collagen I matrix than in 2D cultures (Figure 14A); miRNA Cp 
average was calculated on the base of the 156 commonly expressed miRNAs; the 
analysis of the average highlights that miRNA expression was more induced in 
3D sample rather than in 2D culture (Figure 14B). 
Cp average was used to calculate the normalized Cp values which is given by: 
 
Normalized Cp = mean (n=156) – assay Cp 
 
Figure 14C shows the heat map diagram and the hierarchical clustering of 
microRNAs and samples. It is a representation of the miRNAs with the highest 
differential detection; for this analysis the normalized (∆Cp) values were used. 
Each row represents one microRNA and each column represents one sample, 
CSCs in 2D culture and CSCs in collagen three-dimensional matrix. The 
microRNA-clustering tree, shown on the left, was performed on the top 50 
microRNAs with the higher standard deviation. The color scale shown at the 
bottom, illustrates the relative expression level of a microRNA across all samples: 
red color represents an expression level above the mean, green color represents 
expression lower than the mean. The right part of the heat map shows at the top  
the list of microRNAs which were more expressed in 3D cultures rather than in 
2D cultures; at the bottom are listed miRNAs that were downregulated.  
In order to understand how many times each miRNA was increased in 3D cultures 
compared to the 2D cultures, the fold change, expressed as 2-∆∆Cp , was calculated 
[102]. The panels D-E of the Figure 14 show the graphic representation of the 
most differentially expressed miRNAs comparing the two sample types. Among 
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50 differentially expressed miRNAs, 12 showed fold change > 1, 13 had fold 
change < 1. 
 
 
 
 
 
 
Figure 14. microRNA expression in bi and three-dimensional culture of CPCs. 
A) Total miRNA count, B) miRNA Cp average, C) heat map and hierarchical clustering, 
D) miRNA upregulated in CSCs grow in 3D collagen matrix E) miRNA downregulated 
in CSCs grow in 3D collagen matrix. 
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4.2.5 miR-135a and miR-140 are most differentially expressed in three-
dimensional CSC culture 
 
MicroRNA qRT-PCR service revealed that the most differentially expressed 
miRNAs in 3D cultures were miR-135a and miR-140 which exhibited a fold 
change of 30,5 and 12,1, respectively.  
In order to understand if these miRNAs were conserved among species, a 
comparison between sequences were performed using CLC Main Workbench 5.7 
software; as shown in figure 15, both considered miRNAs are perfectly conserved 
among rat, mouse, zebrafish and human. 
The following step after the discovery of new miRNAs involved in a specific 
biological event is the study of their potential targets. To achieve this purpose we 
used one of the most widely spread engines, TargetScan (www.targetscan.org) 
and subsequently, DAVID bioinformatics resources (www.david.abcc.ncifcrf.gov)  
[103] for extracting biological meaning from large protein lists given by 
TargetScan.  
Myocytes-enhancer factor-2 (Mef2c) is predicted to be targeted by miR-135a 
(Figure 16A). As can be observed, miR-135a binding site is highly conserved 
along the Mef2c 3’UTRs in other species (Figure 16B). Panel C of Figure 16 
displays the conserved position of Mef2c 3’UTR which interacts with miR-135a 
seed sequence.  
Target prediction analysis by TargetScan revealed that Hand2, and the regulator 
of differentiation 1 (Rod1), could be potential targets of miR-140 (Figure 17A and 
18A). The highly conservation along the Hand2 and Rod1 3’UTRs of miR-140 
binding site and the conserved position of Hand2 and Rod1 3’UTR which 
interacts with miR-140 seed sequence, are shown (Figure 17 B-C and 18 B-C). 
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Figure 15. miRNA sequence comparison among rat, zebrafish, human and mouse. miR-
135 a (A) and miR-140 (B) are conserved among species. 
 
 
 
 
Figure 16. TargetScan analysis of putative miR-135a binding site in the rat Mef2c 
transcription factor 3’UTR. miR-135a is a putative microRNA targeting Mef2c (A) and 
its binding site is highly conserved along the Mef2c 3’UTR in other species (B). 
According to the common parameters that have to be considered, Mef2c can be 
considered a good potential target of miR-135a (C). 
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Figure 17. TargetScan analysis of putative miR-140 binding site in the rat Hand2 
3’UTR. miR-140 is a putative microRNA targeting Hand2 (A) and its binding site is 
highly conserved along the Hand2 3’UTR in other species (B). According to the common 
parameters that have to be considered, Hand2 can be considered a good potential target of 
miR-140 (C). 
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Figure 18. TargetScan analysis of putative miR-140 binding site in the rat Rod1 
3’UTR. miR-140 is a putative microRNA targeting Rod1 (A) and its binding site is 
highly conserved along the Rod1 3’UTR in other species (B). According to the common 
parameters that have to be considered, Rod1 can be considered a good potential target of 
miR-140 (C). 
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5. DISCUSSION 
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5.1 Localization of cardiac stem cell and study of the expression of miRNAs 
in human embryos and fetuses  
 
The discovery of cardiac stem cells that live in the heart and can differentiate into 
cardiac cell lineage, has definitely determined the shift in the ancient paradigm 
that heart was a terminally differentiated postmitotic organ. Several categories of 
cardiac stem cells have been described. 
Cardiac progenitor cells can be isolated from adult and post natal hearts [104]; 
[59] and can be identified through the expression of several markers as c-Kit, both 
in fetal [67] and adult hearts [51], Isl-1 during early cardiogenesis [59]; [61] and 
CD105 in human endomyocardial biopsy specimens [56]. 
With regard to these markers, in this study we focused on the localization and 
temporal distribution of c-Kit+/CD105+ and Isl-1+ cells from the embryonic to the 
postnatal hearts; furthermore, we tested whether c-Kit-positive cells were also 
present in the embryonic and fetal heart and if they represented a subset of cells 
different from the Isl-1+ cell population. 
In an attempt to define the temporal distribution and the localization of cardiac 
precursor cells in human hearts at different gestational ages, 
immunohistochemistry and immunofluorescence analysis were performed.  We 
found that Isl-1-positive cells are present in fetuses, preterm infant and term infant 
human hearts. Their number decreased with the advancing of gestational age, in 
particular after the 16-19th week. Moreover we found that cardiomyocytes and 
some interstitial cells were positive to c-Kit from the 9th to the 16-19th gestational 
week but after this time period, the number of interstitial c-Kit-positive cells 
decreased. On the other hand, interstitial cells, which were double positive for c-
Kit and CD105, were present only from 17th week to the 6th year of age. However, 
the presence of c-Kit/CD105 double positive cells in the different gestational 
stages does not demonstrate that c-Kit+ cells are resident cardiac cells, but the fact 
that many structures in the embryonic heart and fetal cardiomyocytes express c-
Kit provides evidence that c-Kit+ cells are present in the heart from the early 
stages of cardiogenesis and that their number decreases with the proceeding of 
gestation until the postnatal age.  
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Moreover, Isl-1 and c-Kit co-localize in interstitial and subendocardial cells; the 
co-localization of the two CPC markers let us suppose that Isl-1+ cells are a 
subset of the c-Kit+ cardiac progenitor cell population. These findings are 
supported by a recent paper in which the authors isolated from neonate and infant 
specimens a pool of c-Kit positive CPCs that were also positive to Isl-1 in culture 
inside cardiospheres [105]. 
Several evidences demonstrate that microRNAs play a key role in cardiac 
development and cell differentiation, especially miR-1 and miR-133 are 
considered the main regulators in cardiogenesis [45], [77] and in cardiomyocytes 
differentiation [73]. In regard to literature, we wanted to investigate changing of 
the expression levels of miR-1 and miR-133 in human embryonic and fetal hearts 
during different gestational ages. In order to achieve our purpose we performed in 
situ hybridization analysis using miRCURY LNA™ DIG-labeled detection probes 
and we found that  samples at 16th, 20th and 32nd week were positive to miR-1 and 
miR-133 with no appreciable variation in the different gestational weeks. In an 
attempt to define a kinetic profile of miR expression, the signal was quantified 
and, in spite of what was observed by visual analysis of the signal, miRNA 
expression was subject to variations: miR-133 levels significantly increased at 20th 
gestational week and decreases at 32nd week; on the other hand, miR-1 did not 
undergo to significant variations. 
These findings suggest that, even if the heart is completely formed at 16th 
gestational week, cycles of proliferation and differentiation are still present, 
supporting once again that heart is not a static organ. 
 
 
 
 
 
 
75 
 
5.2 Investigation on miRNA expression pattern in cardiac stem cell in vitro 
differentiation 
 
Since human heart specimens were difficult to obtain and no more information 
about microRNAs were recoverable, we focused our study on cardiac precursor c-
Kit-positive cells isolated from adult rat heart.  
According to literature, cardiac stem cells reside in the mammalian heart from the 
embryonic age till the adulthood, thus CSCs appear to represent ideal candidate 
for cardiac repair after injury. In fact, the challenge of cardiac regeneration is to 
find the best way to induce cardiac stem cell differentiation in the damaged heart. 
The present studies on CPCs and their clinical applications regards the 
intramyocardial or intracoronary injection of cells. The injected cells disperse in 
the myocardial tissue and regenaration is very poor. A nice way to deliver CPCs 
in a damaged myocardium could be to use biomaterials. Moreover, the study of 
the expression of microRNAs in CSCs, whose overexpression can promote 
lineage commitment, could be useful for stimulation of in vitro and in vivo cell 
fate decision [68]. 
For all these reasons in the present study we focused on the analysis of the 
microRNA expression pattern in CSCs in 2D and 3D cultures, during their 
differentiation process. 
Cardiac stem cells from adult rat myocardium were isolated and after 10 days 
characterized for the expression of some stem cell markers on the cell membrane. 
Flow cytometric analysis revealed that these cells are largely positive for all the 
three considered markers: c-Kit, Sca-1 and MDR-1. In order to stimulate CSC 
differentiation, three-dimensional cultures in PLLA scaffolds and collagen I 
matrix alone were performed. Morphological analysis of CPCs in 3D cultures 
showed a higher state of differentiation of CPCs in 3D cultures compared with 2D 
cultures; particularly, cytoplasm of CPCs grown in a collagen I matrix seemed to 
be more granular than cytoplasm of CPCs grown in P(d,l)LA or BD scaffolds. 
Since 3D cultures in P(d,l)LA scaffolds were prepared first embedding cells in 
collagen I, this evidence let us suppose that collagen I itself is responsible of 
differentiation. 
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Molecular analysis of the expression pattern of ECM coding genes, ECM 
receptors, downstream signaling molecules and cardiac specific genes confirmed 
this hypothesis. Comparison between the expression pattern of cells grown in 3D 
BD or P(d,l)LA scaffolds and cells in collagen I 3D-matrix revealed that genes 
encoding for ECM molecules, integrins, cardiac-specific proteins were more 
expressed in presence of collagen I only. This finding suggests once more time 
that collagen I is a fundamental component for cell differentiation. 
For this reason we decided to investigate on the expression pattern of microRNAs 
in order to understand which miRNA was more induced during cardiac stem cell 
differentiation mediated by the presence of biomaterial.  
The analysis of the genomic localization of the most differentially expressed 
miRNAs in three-dimensional collagen matrix cell cultures revealed that a 
substantial number of these miRNAs are located in intergenic regions (13/25, 
52%), a big part were intronic (11/25, 44%), whereas the rest were exonic (1/25, 
4%). As reported by Callis and colleagues in 2009, transcriptional regulation of 
gene-embedded microRNAs is modulated in accordance with transcriptional 
regulation of the host gene [106]. On the other hand, the transcriptional regulation 
of intergenic miRNAs remains largely unknown. Interestingly, in our case, several 
intergenic miRNAs are clustered in genomic regions and they can be transcribed 
as single polycistronic units and subsequently processed into single pre-miRNA 
molecules [107]. 
Surprisingly, the miRNAs whose expression we studied in embryonic and fetal 
hearts, miR-1 and miR-133, were not expressed.  However, we found several 
miRNAs which were differentially expressed in CSCs grown in three-dimensional 
collagen I matrix rather than in CSCs grown in 2D cultures. In particular, miR-
135a and miR-140 were the most differentially expressed miRNAs exhibiting the 
highest fold change. 
MiR-135a is an intergenic miRNA whose gene is localized in the q13 of the 
chromosome 7 together with several quantitative trait loci (QTLs). A QTL is a 
chromosomal region suspected to contain a gene (or cluster of genes) that 
contributes to the variation observed at a quantitative trait; cardiac mass QTL6, 
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found in q13 of the chromosome 7, could be interesting to investigate, in order to 
understand whether there is a correlation with miR-135a expression. 
MiR-140 is an intronic miRNA localized within the intron of NEDD4-like E3 
ubiquitin-protein ligase WWP2 (intron16). 
In literature there are still no evidence that these miRNAs are directly involved in 
cardiac stem cell differentiation, but in silico analysis of their predicted target 
revealed that both miRNAs are implicated in the regulation of two important 
cardiac-specific transcription factors: Mef2c (predicted target of miR-135a) and 
Hand2 and (predicted target of miR-140). Another potential target of miR-140 is 
Rod1, an RNA binding protein that negatively modulates cell differentiation 
[108]. In a recent paper, it has been demonstrated that Rod1 is a target of miR-
499; in human CSCs, the repression of Rod1 miR-499-mediated enhanced 
cardiomyogenesis in vitro and after infarction in vivo [109]. 
Mef2c is a highly relevant transcription factor crucial for skeletal and cardiac 
myogenesis [110]. 
Hand2 is a transcription factor that promotes ventricular cardiomyocyte expansion 
[111]. It is a member of the basic helix loop helix (bHLH) family of transcription 
factors and is expressed in numerous cell lineages that contribute to the 
developing heart. Recently it has been demonstrated that, during cardiogenesis, 
Hand2, is essential for survival of second heart field progenitors and that the 
graded loss of Hand2 function in this cardiac progenitor pool can cause a 
spectrum of congenital heart malformation [112]. 
To study the interaction between miRNA and its target, several factors have to be 
assessed. Since a single miRNA can target hundreds of distinct mRNAs through 
seed-matched sites [113], it is important to consider that not every site is effective: 
8-nt sites are effective more often than 7-nt sites, which are effective more often 
than 6-nt sites [29], [32]. Furthermore, another important factor is the site context. 
For example, sites into the 3’UTR are effective more often than those in the path 
of the ribosome, but among 3’UTR sites, those away from the centers of long 
UTR and within A-U sequence context are more often effective [29]. Other two 
important parameters that can influence the targeting efficacy are the weak 
predicted seed-pairing stability (SPS), which is a function  of the concentration of 
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A+U in the seed region, and the high target side abundance (TA), which reflects 
the abundance of target sites of a miRNA family in the set of distinct 3' UTRs  
[114]. Thus, a negative score of SPS is associated with weaker seed-pairing 
stability and a negative score of TA is associated with a lower abundance of the 
miRNA target site in the set of 3' UTRs [114]. The sum of the contribution of all 
considered parameters (the site type, the local A+U content, the location of the 
site within the 3’UTR, SPS and TA) contributes to calculate the context+ scores 
for each predicted target of each miRNA. The most favorable context+ score is 
the lowest value [114]. 
According to these rules, as shown in Figure 16, 17 and 18, an accurate evaluation 
of the TargetScan results revealed that Mef2c, Hand2 and Rod1 seems to be good 
candidates for regulation mediated by miR-135a and miR-140.  
In a recent work performed in 2010 by Chinchilla and colleagues, Mef2c were 
demonstrated to be also targeted by miR-27b, which is differentially expressed 
from early stages of ventricular chamber formation [115]. In the same work, the 
authors demonstrated that even miR-135a and miR-140 were expressed during the 
early stages of ventricular maturation [115]. 
Future investigation of the full spectrum of genes that a single miRNA may target 
in a given context, how these targets functionally interact, may improve our 
understanding of their role in the CPC biology in order to enhance cardiac stem 
cell ability in differentiation. 
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